Key Product Details
Product Summary for Human FGF‑BP Antibody
Accession # Q14512
Applications for Human FGF‑BP Antibody
Sample: Recombinant Human FGF-BP (Catalog # 1593-FB)
Read 2 publications using AF1593 in the following applications:
Formulation, Preparation and Storage
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Fibroblast growth factor binding protein (FGF‑BP), also known as HBp17, is a secreted glycoprotein that increases the bioavailability of FGFs (1). Mature FGF-BP is a 34 kDa, 211 amino acid (aa) O-glycosylated protein with five conserved intrachain disulfide bonds (2‑4). FGF-BP contains a heparin-binding domain (aa 110‑143) and a distinct FGF-binding region (aa 193‑243) (5). Mature human FGF‑BP shares 59% and 54% aa sequence identity with mouse and rat FGF-BP, respectively. FGF-BP is expressed throughout development and in adult squamous epithelium (2, 6). It is upregulated in injured skin, renal tubular epithelium, and spinal nerves as well as in carcinomas of the skin, colon, and pancreas (3, 7‑10). FGF-BP binds FGF-1, -2, -7, -10, and -22 which are secreted and sequestered in the extracellular matrix (ECM) (7, 11). The association of FGF-BP with heparan sulfate proteoglycans (HSPG) weakens HSPG attachment of FGFs and promotes their release (2, 8, 12, 13). FGF‑BP enhances the mitogenic effects of FGFs, thereby contributing to epithelial, endothelial, and neuronal tissue repair, angiogenesis, and tumor growth (7‑9, 11, 14, 15).
- Abuharbeid, S. et al. (2006) Int. J. Biochem. Cell Biol. 38:1463.
- Wu, D. et al. (1991) J. Biol. Chem. 266:16778.
- Tassi, E. et al. (2006) Cancer Res. 66:1191.
- Lametsch, R. et al. (2000) J. Biol. Chem. 275:19469.
- Xie, B. et al. (2006) J. Biol. Chem. 281:1137.
- Aigner, A. et al. (2002) Histochem. Cell Biol. 117:1.
- Beer, H-D. et al. (2005) Oncogene 24:5269.
- Ray, P.E. et al. (2006) Am. J. Physiol. Regul. Integr. Comp. Physiol. 290:R105.
- Tassi, E. et al. (2007) Am. J. Physiol. Regul. Integr. Comp. Physiol. 293:R775.
- Kurtz, A. et al. (2004) Neoplasia 6:595.
- Tassi, E. et al. (2001) J. Biol. Chem. 276:40247.
- Mongiat, M. et al. (2001) J. Biol. Chem. 276:10263.
- Kurtz, A. et al. (1997) Oncogene 14:2671.
- Aigner, A. et al. (2001) Int. J. Cancer 92:510.
- Czubayko, F. et al. (1997) Nat. Med. 3:1137.
Product Specific Notices for Human FGF‑BP Antibody
For research use only